Clinical trial
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00041236 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00041236 |
|---|---|
| Title | Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma |
| Official title | Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Enrollment | 39 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2012 |
| Countries | Belgium, Denmark, Germany, Slovakia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: